1. Home
  2. ERAS vs FUFU Comparison

ERAS vs FUFU Comparison

Compare ERAS & FUFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • FUFU
  • Stock Information
  • Founded
  • ERAS 2018
  • FUFU 2020
  • Country
  • ERAS United States
  • FUFU Singapore
  • Employees
  • ERAS N/A
  • FUFU N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • FUFU
  • Sector
  • ERAS Health Care
  • FUFU
  • Exchange
  • ERAS Nasdaq
  • FUFU NYSE
  • Market Cap
  • ERAS 719.0M
  • FUFU 744.5M
  • IPO Year
  • ERAS 2021
  • FUFU N/A
  • Fundamental
  • Price
  • ERAS $2.67
  • FUFU $5.40
  • Analyst Decision
  • ERAS Strong Buy
  • FUFU
  • Analyst Count
  • ERAS 5
  • FUFU 0
  • Target Price
  • ERAS $6.10
  • FUFU N/A
  • AVG Volume (30 Days)
  • ERAS 1.7M
  • FUFU 140.9K
  • Earning Date
  • ERAS 11-12-2024
  • FUFU 11-05-2024
  • Dividend Yield
  • ERAS N/A
  • FUFU N/A
  • EPS Growth
  • ERAS N/A
  • FUFU 1042.93
  • EPS
  • ERAS N/A
  • FUFU 0.23
  • Revenue
  • ERAS N/A
  • FUFU $452,743,012.00
  • Revenue This Year
  • ERAS N/A
  • FUFU N/A
  • Revenue Next Year
  • ERAS N/A
  • FUFU N/A
  • P/E Ratio
  • ERAS N/A
  • FUFU $23.00
  • Revenue Growth
  • ERAS N/A
  • FUFU 78.43
  • 52 Week Low
  • ERAS $1.51
  • FUFU $2.32
  • 52 Week High
  • ERAS $3.45
  • FUFU $18.32
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 43.56
  • FUFU 59.36
  • Support Level
  • ERAS $2.59
  • FUFU $5.10
  • Resistance Level
  • ERAS $3.19
  • FUFU $6.05
  • Average True Range (ATR)
  • ERAS 0.20
  • FUFU 0.59
  • MACD
  • ERAS -0.02
  • FUFU 0.05
  • Stochastic Oscillator
  • ERAS 20.13
  • FUFU 59.85

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About FUFU BITFUFU INC

BitFuFu Inc is a digital asset mining and cloud-mining service provider that fosters a secure, compliant, and transparent blockchain infrastructure. It provides stable and intelligent digital asset mining solutions, including one-stop cloud-mining services and miner hosting services to institutional customers and individual digital assets.

Share on Social Networks: